Search Results - "González Manzano, Ramón"

RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer by Manzano, Ramon Gonzalez, Catalan-Latorre, Ana, Brugarolas, Antonio

“…Muscle invasive urothelial bladder carcinoma (MIBC) present RB1 and TP53 somatic alterations in a variable percentage of tumors throughout all molecular…”
Get full text

Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies by Mata-Molanes, Juan J., Rebollo-Liceaga, Joseba, Martínez-Navarro, Elena Mª, Manzano, Ramón González, Brugarolas, Antonio, Juan, Manel, Sureda, Manuel

“…Therapeutic monoclonal antibodies (mAbs), including immune checkpoint inhibitors (ICIs), are an important breakthrough for the treatment of cancer and have…”
Get full text

Immunological profile could be responsible of the unusual long-lasting cutaneous-only breast cancer recurrence: An observational study by Rebollo, Joseba, González-Manzano, Ramón, Sureda, Manuel, Martínez, Elena Ma, Monedero, Elena, Bretcha, Pedro, Brugarolas, Antonio

“…e13000 Background: A small number of breast cancer patients develops long-lasting loco-regional cutaneous recurrent disease with a delayed appearance of…”
Get full text

Transcriptome (RNA next generation sequencing) for personalizing of cancer treatment: A correlation with previous clinical resistance by Sureda, Manuel, Rebollo, Joseba, González-Manzano, Ramón, Martínez, Elena Ma, Rostagno, Roman, Mata, Juan José, Monedero, Elena, Ortega, Jose, Brugarolas, Antonio

“…Abstract only e15046 Background: RNA Next Generation Sequencing (transcriptome) is a potential useful tool to predict chemoresistance to available anticancer…”
Get full text

DNA and RNA next generation sequencing for personalizing cancer treatment: A single-center experience by Rebollo, Joseba, Sureda, Manuel, González-Manzano, Ramón, Martínez, Elena Ma, Rostagno, Roman, Mata, Juan José, Monedero, Elena, Ortega, Jose, Brugarolas, Antonio

“…Abstract only e13509 Background: Personalized multidrug therapies improve outcomes in patients with drug resistant cancer. For 8 years we have been using…”
Get full text

A Patient With Metastatic Sarcoma was Successfully Treated With Radiolabeled Somatostatin Analogs by Crespo-Jara, Aurora, González Manzano, Ramón, Lopera Sierra, Maribel, Redal Peña, María Carmen, Brugarolas Masllorens, Antonio

“…ABSTRACTWe present a sarcoma patient with a tumor reduction of more than 50% in lung metastasis after 2 single courses of the investigational medical product…”
Get full text

A novel genomic signature predicting FDG uptake in diverse metastatic tumors by Crespo-Jara, Aurora, Redal-Peña, Maria Carmen, Martinez-Navarro, Elena Maria, Sureda, Manuel, Fernandez-Morejon, Francisco Jose, Garcia-Cases, Francisco J., Manzano, Ramon Gonzalez, Brugarolas, Antonio

“…Background Building a universal genomic signature predicting the intensity of FDG uptake in diverse metastatic tumors may allow us to understand better the…”
Get full text

Clinical activity of antineoplastic drugs selected by tumor oligonucleotide expression microarrays (MP) in advanced and refractory cancer patients by Rebollo, Joseba, Sureda, Manuel, González-Manzano, Ramón, Fernández-Morejón, Francisco J., Farré, José, Fernández-Latorre, Francisco, Vegas, Jesús, Martínez, Elena Ma, Bretcha, Pedro, Brugarolas, Antonio

“…Abstract only…”
Get full text

A novel EGFR nonsense mutation in a non-small-cell lung cancer (NSCLC) patient who did not derive any clinical benefit with combination chemotherapy and erlotinib by Manzano, Ramón González, Navarro, Elena Martínez, Eugenieva, Elena, Morejón, Francisco José Fernández, Farré, José, Brugarolas, Antonio

“…Most of the somatic epidermal growth factor receptor (EGFR) mutations described to date in non-small-cell lung cancer (NSCLC) patients are located in the…”
Get full text

Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs) by Martínez-Navarro, Elena María, Rebollo, Joseba, González-Manzano, Ramón, Sureda, Manuel, Evgenyeva, Elena, Valenzuela, Belén, Fernández, Francisco José, Forteza, Jerónimo, Brugarolas, Antonio

“…Introduction Epidermal growth factor receptor (EGFR) mutation related to tyrosine kinase inhibitors’ (TKIs) responsiveness in non-small cell lung cancer…”
Get full text

Abstract 2213: Influence of genetic polymorphism in UGT1A1, UGT1A7 and UGT1A9 on irinotecan, SN-38 and SN-38G pharmacokinetics by Valenzuela, Belen, González-Sales, Mario, Escudero, Vanessa, Navarro, Elena, Perez-Ruixo, Carlos, Rebollo, Joseba, González-Manzano, Ramon, Pérez-Ruixo, Juan José

“…Background and objective: SN-38 is the active metabolite of irinotecan (CPT-11) and mainly responsible of hematological and intestinal toxicity after CPT-11…”
Get full text

Contribution of microarrays of gene expression (MAGE) to the definition of PET/CT as a qualified biomarker of early response in metastatic patients by Sureda, Manuel, Crespo-Jara, Aurora, Gonzalez Manzano, Ramon, Redal, Maria del Carmen, Garcia-Cases, Francisco Javier, Martinez Navarro, Elena Mª, Brugarolas, Antonio

“…Abstract only 11573 Background: Proliferating cancer cells consume elevated quantity of glucose, converted into lactate regardless the presence of oxygen…”
Get full text

Personalized gene expression profiling-guided (MAGE) therapy in heavily treated metastatic breast cancer (MBC): A pilot study by Sureda, Manuel, Rebollo, Joseba, Martínez, Elena Ma, Fernández-Morejón, Francisco J., Munoz, Vicente, Gonzalez Manzano, Ramon, Brugarolas, Antonio

“…Abstract only…”
Get full text

Personalized gene expression profiling-guided (MAGE) therapy in resistant sarcomas. Preliminary data by Sureda, Manuel, Gonzalez Manzano, Ramon, Martínez, Elena Ma, Fernández-Morejón, Francisco J., Rebollo, Joseba, Crespo, Aurora, Valenzuela, Belen, Farre, Josep, Brugarolas, Antonio

“…Abstract only…”
Get full text

Chemotherapy selection by gene expression profiling (MAGE) in resistant/refractory (R/R) patients with solid tumors: A feasibility study by Rebollo, Joseba, Gonzalez-Manzano, Ramon, Fernandez-Morejon, Francisco J., Rey, Severino, Farre, Jose, Sureda, Manuel, Brugarolas, Antonio

“…Abstract only e22120 Background: Genomic-based profiling of tumors is a promising approach that allows the selection of the optimal chemotherapy regimen…”
Get full text

Abstract 4677: Irinotecan plus anthracycline - based combination chemotherapy in advanced solid tumors by Rebollo, Joseba, Sureda, Manuel, Gonzalez-Manzano, Ramon, Balenzuela, Belen, Brugarolas, Antonio

“…Irinotecan and Anthracyclines (Topoisomerase I and II inhibitors, respectively) are widely used as antitumoral agents in cancer treatment. However, no data…”
Get full text

Phase II evaluation of doxorubicin, ifosfamide, and dacarbazine plus amphotericin B in the treatment of metastatic soft tissue sarcomas. A pilot study by González-Manzano, R, Vieitez, J M, Tangco, E, Fernandez de Alava, E, Herranz, P, Garcia-Foncillas, J

“…Amphotericin B enhances the cytotoxicity of certain antineoplastic agents in vitro and in vivo. A phase II study was designed to evaluate whether this effect…”
Get more information

Modulation by acrolein and chloroacetaldehyde of multidrug resistance mediated by the multidrug resistance-associated protein (MRP) by GONZALEZ MANZANO, R, WRIGHT, K. A, TWENTYMAN, P. R

“…Acrolein (AC) and chloroacetaldehyde (CHA) are metabolites of the non-multidrug resistance cytotoxic drugs cyclophosphamide and ifosfamide. It has previously…”
Get full text

Epoch-cyclosporin A induces high response rates in relapsed lymphomas by LOPEZ-PICAZO, Jose M, GONZALEZ MANZANO, Ramon, ORDONEZ TRES, Jose M, MORENO JIMENEZ, Marta, PEREZ CALVO, Javier, BRUGAROLAS, Antonio

Get full text

Evolution of plasminogen-related growth factors (HGF/SF and HGF1/MSP) by Gherardi, E, Gonzalez Manzano, R, Cottage, A, Hawker, K, Aparicio, S

“…HGF/SF and HGF1/MSP define a novel growth factor family whose members share the domain structure and the proteolytic process of activation of the blood…”
Get more information